Weekly Patent Roundup

Weekly Patent Roundup

Federal Circuit disqualifies Katten from Mylan appeals

The US Court of Appeals for the Federal Circuit yesterday disqualified law firm Katten Muchin Rosenman from representing Mylan in three appeals before the court. In a precedential decision handed down on February 20, the Federal Circuit ruled that Katten’s representation of subsidiaries of Canadian pharma company Valeant Pharmaceuticals International presented a conflict of interest…..

Accord vs. NPS; District Court of The Hague 6 February 2019 [Cinacalcet]

Shire-NPS Pharmaceuticals Inc. (“NPS”) was the patentee of EP 1 203 761 B1 (“EP 761”) titled “Calcium receptor-active compounds” that was granted on 19 January 2005. The subject matter of EP 761 is, inter alia, the pharmaceutical compound cinacalcet, which is used for the treatment of hypercalcemia and related diseases (in essence, cinacalcet, helps the body maintaining normal calcium levels). On the basis of EP 761, a supplementary protection certificate was granted by the Dutch Patent Office to Amgen for the product Mimpara (the “SPC”) which SPC expires on 25 April 2020…..

Judge Stark on Privilege for Patent Agents [KYPROLIS® (carfilzomib)]

In a Memorandum Order unsealed on February 19, Chief Judge Stark addressed disputes over Plaintiff Onyx’s privilege log. Before making rulings on specific documents reviewed in camera, Judge Stark ruled generally as to the extent of the applicable privilege. Judge Stark first recognized that the Federal Circuit has recognized a privilege between non-attorney patent agents and their clients, but that such a privilege is narrow. Onyx Therapeutics, Inc. v. Cipla Limited, C.A. No. 16-988-LPS….

Amgen Asks Fed. Circ. To Uphold $70M Hospira IP Verdict [EPOGEN® (Epoetin alfa)]

Law360 (February 21, 2019, 4:52 PM EST) — Amgen Inc. has asked the Federal Circuit to preserve a $70 million jury verdict finding that Hospira’s biosimilar version of the blockbuster anemia treatment Epogen infringed an Amgen patent, saying Hospira…
Indian court says Sinopharm Weiqida’s amoxicillin trihydrate product infringes Centrient patent

Netherlands-based Centrient Pharmaceuticals, a manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate……

Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2023 Pharma IP Circle. All Rights Reserved